{
    "nct_id": "NCT04619797",
    "official_title": "A Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Patients With Previously Untreated Advanced Non-Squamous Non-Small-Cell Lung Cancer",
    "inclusion_criteria": "* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n* Histologically or cytologically documented locally advanced unresectable or metastatic non-squamous NSCLC that is not eligible for curative surgery and/or definitive chemoradiotherapy\n* No prior systemic treatment for metastatic non-squamous NSCLC\n* Known tumor programmed death-ligand 1 (PD-L1) status\n* Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1)\n* Life expectancy >= 12 weeks\n* Adequate hematologic and end-organ function\n* Negative human immunodeficiency virus (HIV) test at screening\n* Serology test negative for active hepatitis B virus or active hepatitis C virus at screening.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Mutations in epidermal growth factor receptor (EGFR) gene or anaplastic lymphoma kinase (ALK) fusion oncogene\n* Pulmonary lymphoepithelioma-like carcinoma subtype of NSCLC\n* Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases\n* Active or history of autoimmune disease or immune deficiency\n* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis\n* History of malignancy other than NSCLC within 5 years prior to randomization, with the exception of malignancies with a negligible risk of metastasis or death\n* Severe infection within 4 weeks prior to initiation of study treatment or any active infection that, in the opinion of the investigator, could impact patient safety\n* Treatment with investigational therapy within 28 days prior to initiation of study treatment\n* Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-cytotoxic T lymphocyte-associated protein 4, anti-TIGIT, anti-PD-1, and anti-PD-L1 therapeutic antibodies\n* Treatment with systemic immunostimulatory agents within 4 weeks or 5 drug-elimination half-lives (whichever is longer) prior to initiation of study treatment\n* Treatment with systemic immunosuppressive medication within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment\n* Known allergy or hypersensitivity or other contraindication to any component of the chemotherapy regimen the participant may receive during the study\n* Women who are pregnant, or breastfeeding\n* Known targetable c-ROS oncogene 1 (ROS1) or BRAFV600E genomic aberration.",
    "miscellaneous_criteria": "Key"
}